# Eurobail

> Eurobail is a VC fund in Paris backing Oncology, Health Care and Life Science. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 2
- Last investment: Sep 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/eurobail-formation
- Website: https://eurobail-formation.fr

Eurobail is a specialized training company that works in the real estate, banking, and insurance industries.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Oncology | 1 | 50% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Corporate Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biomunex | BIOMUNEX is a French biopharmaceutical company, founded in 2014 in Paris, focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs.Based on its unique proprietary platform, BIOMUNEX is developing cutting-edge immunotherapies for several cancer types.Its ‘Plug and Play’ modular bispecific antibody BiXAb platform enables BIOMUNEX to develop drug candidates with high anti-tumor potential, superior manufacturability and optimal drug-like properties.The BiXAb platform can also generate innovative bispecific antibodies in any other therapeutic areas, such as immune-mediated inflammatory diseases or infectious diseases or any other diseases in which therapeutic bispecific antibodies may provide benefit.The most advanced candidate derived from BIOMUNEX’ platform, BMX-002, has demonstrated superior in vivo efficacy in pancreatic cancer, one of the most lethal cancers. Initial preclinical studies have proven its potential to become a breakthrough therapy in several solid tumors such as head & neck, gastric or colon cancers.The BIOMUNEX 2nd lead candidate, BMX-101, an immunotherapeutic being developed for multiple myeloma and other hematological malignancies, leverages the power of immune checkpoint inhibition.Research programs are ongoing with renowned academic teams, such as Institut de Recherche en Cancérologie de Montpellier; new programs are being established with additional academic teams.The management team is represented by an experienced group of international managers and drug developers from the pharmaceutical and biotech industries, with extensive scientific expertise in oncology. |  | Corporate Round | Sep 30, 2025 |  |
| DocCity | DocCity LifeSciences creates and provides outstanding spaces to house cutting-edge healthcare businesses. DocCity provides clinicians with state-of-the-art, fully furnished health spaces with roomy, well-lit, and digitally equipped consultation rooms and reception areas. | $32.9M | Series A | Nov 27, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [CELESTE](https://shizune.co/investors/profile/celeste) — VC Fund, 1 deal together
- [Eternam](https://shizune.co/investors/profile/eternam) — VC Fund, 1 deal together
- [Florac](https://shizune.co/investors/profile/florac) — VC Fund, 1 deal together
- [MACSF](https://shizune.co/investors/profile/macsf) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Life Science Investors in France](https://shizune.co/investors/life-science-investors-france)
- [Life Science VC Funds in France](https://shizune.co/investors/life-science-vc-funds-france)

## FAQ

### What does Eurobail invest in?

Eurobail invests primarily in Oncology, Health Care and Life Science startups, most often at Series A and Corporate Round stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eurobail last invest?

The most recent investment recorded for Eurobail closed in Sep 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co